UK markets open in 7 hours 7 minutes

Armata Pharmaceuticals, Inc. (ARMP)

NYSE American - Nasdaq Real-time price. Currency in USD
Add to watchlist
2.5700-0.0550 (-2.10%)
At close: 03:58PM EDT
2.6700 +0.10 (+3.89%)
After hours: 07:19PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close2.6250
Open2.6000
Bid2.5500 x 900
Ask3.0000 x 1300
Day's range2.5700 - 2.6500
52-week range1.0700 - 5.2600
Volume4,619
Avg. volume15,052
Market cap92.917M
Beta (5Y monthly)0.83
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
All
News
  • PR Newswire

    Armata Pharmaceuticals Announces First Quarter 2024 Results and Provides Corporate Update

    Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on high-purity, pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced financial results for its first quarter ended March 31, 2024, and provided a corporate update.

  • PR Newswire

    Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2023 Results and Provides Corporate Update

    Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on high-purity, pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced financial results for its fourth quarter and full-year ended December 31, 2023, and provided a corporate update.

  • PR Newswire

    Armata Pharmaceuticals Announces $35 Million Secured Credit Agreement with Innoviva

    Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that it has entered into a secured credit agreement with Innoviva Strategic Opportunities LLC, a wholly-owned subsidiary of Innoviva, Inc. (Nasdaq: INVA) (collectively, "Innoviva"), Armata's largest shareholder. The gross proceeds to be received by the C